ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Antibiotic Resistance and New Antimicrobial drugs
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1608897
This article is part of the Research TopicWomen in Biofilms: 2025View all articles
Biotherapeutic potential of different fractions of cell-free supernatants from Lacticaseibacillus rhamnosus against Pseudomonas aeruginosa
Provisionally accepted- 1Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Tuscany, Italy
- 2Department of Biology, Maynooth University, Maynooth, County Kildare, Ireland
- 3Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Due to their content of multiple antimicrobial bioactive substances, cell-free supernatants (CFS) from lactic acid bacteria are emerging as novel antimicrobials. We have previously demonstrated that CFS from Lacticaseibacillus rhamnosus exert strong antibacterial and antibiofilm activity against Pseudomonas aeruginosa isolated from chronic infections. Herein, we sought to identify the CFS fraction(s) responsible for such activities and characterize the same CFS in terms of immunomodulatory properties and protein content. Methods: A P. aeruginosa clinical isolate was used in the study. CFS fractions were obtained by 3 kDa cut-off size-exclusion filtration. The antibacterial and antibiofilm activity of unfractionated and fractionated CFS was tested on planktonic and biofilm-associated P. aeruginosa using colony-forming unit enumeration, crystal violet staining, and confocal microscopy. Label-free qualitative proteomic was performed using a shotgun approach with mass spectrometry to characterize the protein content of the CFS. Additionally, the immunomodulatory effects of the CFS were evaluated on human peripheral blood mononuclear cells (PBMC) stimulated with P. aeruginosa lipopolysaccharide (LPS) or biofilm derived P. aeruginosa cells. Results: Both antibacterial and antibiofilm activities were mainly, but not exclusively, ascribed to the low molecular weight CFS fraction (≤ 3 kDa), which contained most of the lactic acid, suggesting a major role of this component in the antimicrobial effect of CFS. The > 3 kDa fraction alone was almost inactive but displayed a synergistic antibacterial effect when reconstituted with the ≤ 3 kDa fraction. Proteomics analysis of CFS revealed the presence of cell wall hydrolases, suggesting that these enzymes might contribute to the antibacterial activity observed in the reconstituted fractions. Following 6 h stimulation of PBMC with LPS or biofilm-derived P. aeruginosa, a marked anti-inflammatory effect was exhibited by unfractionated CFS as well as ≤ 3kDa fraction at non-toxic concentrations, while the > 3kDa fraction was found to induce the production of IL-6, TNF-α, and to a lesser extent of IL-10. Conclusion: The obtained results support that, due to their multiple antimicrobial and anti-inflammatory effects, probiotic metabolites might represent a promising strategy for the prevention and/or treatment of chronic infections with an intense inflammatory response such as those caused by P. aeruginosa.
Keywords: Probiotics, Pseudomonas aeruginosa, Biofilm, Proteomics, Immunomodulation, Lacticaseibacillus rhamnosus, PBMC
Received: 09 Apr 2025; Accepted: 03 Jun 2025.
Copyright: © 2025 Bianchi, Kaya, Logiudice, Maisetta, Curtis, Kavanagh, Batoni and Esin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Semih Esin, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.